摘要
目的:评价特异性甲基化PCR(MSP)分析法检测抑癌基因高甲基化对结、直肠癌的诊疗价值.方法:应用MSP法检测36例结、直肠癌患者血清、术中癌旁组织及癌组织中的抑癌基因hMLH1、p15、p16甲基化的发生率.另选择36例健康体检者血清样品作正常对照.结果:36例结、直肠癌患者术前血清及术中癌组织的hMLH1、p15、p16甲基化发生率为59%～97%,癌旁组织略低;术后1周血清中hMLH1、p15、p16与术前比较明显下降(P＜0.01),而正常对照组抑癌基因甲基化发生率均为0.结论:MSP法的建立,直接检测结、直肠癌患者的抑癌基因的高甲基化状态,有助于临床判断和动态观察治疗的效果.
Aim： To evaluate the clinical value of MSP（methylation specific PCR） in detection of tumor suppressor genes methylation in the colorectal cancer. Methods： The prevalence of methylated tumor suppressor genes（hMLH1 ,p15,p16） were evaluated in 36 coloreetal cancer patients by MSP method in serums and the para- cancerous and cancerous tissue sampies obtained at operation, and 36 serum samples obtained from healthy people as normal control. Results： The prevalence study of methylated tumor suppressor genes （hMLH1 ,p15,p16） in serums and cancerous tissue samples obtained from 36 eoloreetal cancer patients showed a percentage of 59% to 97% （the samples were obtained pre- op and during operation respectively）. The pare - canceroustissue samples has a slightly lower percentage. There＇ s an obvious drop of the hMLH1 ,p15,p16 in the serums obtained from 1 week post- operation patients, but the control group＇s has a 0% prevalence rate. Conclusion： The MSP method, which directly tests the colorectal cancer patient＇ s methylated cancer suppressor genes, is a valuable tool in clinical judgment of therapeutic effect.
出处
《暨南大学学报（自然科学与医学版）》
CAS
CSCD
北大核心
2005年第6期812-815,共4页
Journal of Jinan University(Natural Science & Medicine Edition)
基金
广东省医科学科研基金(A2003390)资助项目
